Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | PARG | Q86W56 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016312 | 0.89 | MAPT (0.50) | MMP13SLC22A8HDAC1HDAC6HDAC11 | |
| SCHEMBL17434512 | 0.88 | KDM4E (0.55) | ALDH1A1HPGDTSHRKMT2APARG | |
| SCHEMBL6518639 | 0.87 | KDM4E (0.62) | MMP13SLC22A8HDAC1HDAC6HDAC11 | |
| SCHEMBL6241073 | 0.86 | MMP13 (0.71) | MMP13SLC22A8HDAC1HDAC6HDAC11 | |
| SCHEMBL6529188 | 0.83 | TP53 (0.52) | MMP13SLC22A8HDAC1HDAC6HDAC11 | |
| SCHEMBL7622582 | 0.79 | USP2 (0.61) | HPGDTSHRKMT2AMAPTTP53 | |
| SCHEMBL6747349 | 0.79 | MMP13 (0.62) | MMP13SLC22A8HDAC1HDAC6HDAC11 | |
| SCHEMBL7012936 | 0.78 | MMP13 (0.61) | MMP13SLC22A8HDAC1HDAC6HPGD | |
| SCHEMBL6735741 | 0.78 | MMP13 (0.60) | MMP13SLC22A8HDAC1HDAC6HDAC11 | |
| SCHEMBL28288132 | 0.77 | ALDH1A1 (0.48) | ALDH1A1HPGDTSHRKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| EP-1361873-A4 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1536786-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-02-19 | — | — | US | disclosed |
| WO-2004006913-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1361873-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SLC22A8 315/4885HDAC1 550/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | MMP13 1/4885SLC22A8 1655/4885HDAC1 370/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | MMP13 1/4885SLC22A8 1442/4885HDAC1 205/4885 |
| US-20040034086-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP11, MMP13, MMP10 | MMP13 2/4885SLC22A8 255/4885HDAC1 435/4885 |
| US-20040034085-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP11, MMP13, MMP10 | MMP13 2/4885SLC22A8 147/4885HDAC1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.